Growth delay may occur in all of the common types of hepatic glycogen storage disease' (glucose-6-phosphatase deficiency, type I and type lb;2 debrancher deficiency, type III; and phosphorylase kinase deficiency, type IX). Fine et al,4 in a long term follow up study of four children with type I disease noted severe growth retardation with delayed sexual maturation.
With intensive treatment the growth rate of growth retarded children with type I hepatic glycogen storage disease may increase strikingly.5 6
Children with type III and IX disease may also have delayed sexual maturation but growth retardation is less pronounced.' As longitudinal growth data are limited, we studied the growth of 31 children with these disorders. London) using standard methods.7-9 Three other patients had the clinical features of type I hepatic glycogen storage disease with failure of glycaemic response to both glucagon and galactose, lactic acidaemia, increased hepatic glycogen, but normal activities of glucose-6-phosphatase and fructose 1-6 diphosphatase in liver that had been frozen. These have been classified as type lb.-Two of these patients had neutropenia and a neutrophil mobilitv defect. "' Longitudinal growth data were available from the records of attendance in the outpatients department and where the patients had been referred back to the local medical services the relevant paediatrician was asked for details of the patient's growth. These height data were compared with the normal data of Tanner, Whitehouse, and Takaishi" and height SD scores were calculated as described by those authors. Bone age maturity scores were calculated by the TW2-RUS method.'" During the study 6 of the children with type I and lb disease were started on treatment with regular drinks of a glucose polymer (Caloreen, Roussel) by day and nasogastric tube feeds of the glucose polymer at night;6 they received approximately 0-5 g/kg/hour of glucose throughout the 24 hours (patients A 1, A3, A4, A6, B 1, and B2). Lactose and sucrose in their diet was restricted. All the children with type IX disease were untreated. Five of those with type III were encouraged to take a high protein diet (patients C1, C2, C3, C1, and C12) with a milk drink at night, but this treatment was not followed consistently.
Patients and methods

Results
Height at diagnosis. At the time of diagnosis all of the patients were below the mean for height and some were very short. The mean height SD scores of children with different types of hepatic glycogen storage disease were; type I (mean (SD)) -2-13 (1-45), type lb -2-0 (1-27). type III -2-4 (1-18), and type IX -1-6 (1-27). Where the bone age data were available (14 patients) maturity was found to be delayed by approximately the same extent as height. The mean bone age SD scores were: type I -2-5 (4 patients), type lb -1-5 (2), type III -1-3 (5), and type IX -13 (5).
Longitudinal growth data. Longitudinal growth data presented as height SD scores in these four types of hepatic glycogen storage disease are shown in Figs. I to 4. Untreated, most children with type I and lb grew slowly, tending to fall further below the mean, with no evidence of catch up growth (Figs. I and 2). The oldest child (Al) showed no signs of puberty or catch up growth at the age of 15 years-his bone age being 11 years, height SD score -6-0, and height velocity SD score -2-8. There were, however, three exceptions-two girls and one boy with type I disease (A5, A7, and A8) grew normally without any treatment and without any bone age delay. All of the children with type I and lb disease who were children were prepubertal, with the exception of patient Al who was started on treatment at age 15½/2 years (bone age 11 years) and started puberty at the age of 161/2 years: His final height was 154 cm (limits predicted from parental heights 161 to 178 cm). At the age of 19 years, when growth had ceased, his bone age remained immature at 14 years. One patient (B3) with type lb disease was treated elsewhere by portal diversion3 at the age of 6 years. Growth velocity was unchanged after surgery.
Children with type III hepatic glycogen storage disease also tended to be short at diagnosis but the subsequent pattern of growth differed from children with type I disease (Fig. 3) . In many of the children there was catch up growth during childhood or at the time of puberty.
Five of the children have passed through puberty. Final heights in all were within 2 SD of the adult mean and where parental height data were available, heights were well within target limits.'4 The onset of puberty was delayed in these children (onset 14 to 16 years; menarche 161/2 to 18 years). A typical example is patient C9 who received no treatment. At the age of 8-5 years her height was 2-5 SD below the mean and her skeletal age was 5 years. Puberty began around 15 years of age (skeletal maturation 13-5 years) and she had a normal growth spurt; her final height was +0-6 SD and menarche occurred at 16½/2 years.
Children with type IX disease tended to show gradual catch up growth throughout childhood (Fig.  4) . The heights of two brothers (DI and D2) were -0-9 and -1-7 SD respectively at diagnosis.
Gradual catch up growth occurred and by the age of 11 years their heights were +2-1 and +0 3 respectively. Puberty was not delayed and final heights were within parental height targets.
Discussion
We present longitudinal growth data from 31 patients with hepatic glycogen storage disease. The data are not perfect as they were obtained retrospectively from charts and are likely to be subject to observational errors; but despite this limitation, because of the long period and number of patients studied, clear growth patterns emerge. Untreated, most of the patients with type I and lb disease grew slowly with no catch up growth. There were three exceptions (all with type I disease) who had a mild disease without documented hypoglycaemia and grew normally. The untreated children with type III disease showed growth and pubertal delay but their final heights were normal. Some of the children with type III and all of those with type IX disease showed catch up growth throughout childhood.
Intensive treatment of children with type I and lb disease resulted in catch up growth and the prognosis for growth was excellent if treatment was started early. Treatment also reverses the endocrine abnormalities'5 and may affect favourably the formation of adenomata, ' but it is not without dangers as sensitivity to hypoglycaemia is restored. 17
As some children with type I disease will grow normally without treatment it is clearly not indicated for all patients.
The mechanisms governing growth delay in these children are not clear. We have recently shown that the severity of growth delay can be correlated with endocrine change (principally low concentrations of insulin and somatomedin with raised plasma cortisol)'5 and suggested that these changes are part of an overall adaptation to decreased hepatic glucose production. Those children with mild disease tend to have a normal glucose response during the fasting glucagon test'8 and may be more able to maintain glucose output from the liver. In patients with type III and IX disease glucose release from gluconeogenesis may be sufficient to allow for catch up growth during childhood as the requirement for glucose, expressed per kg body weight, declines after the age of 6 years.'9 glycogenoses. 
Patterns of growth in the hepatic
